Saturday, April 20, 2024

This DNA sequencer fits in the palm of your hand

Must read

Michael Whyte
Michael Whyte
Crime Scene Officer and Fingerprint Expert with over 13 years experience in Crime Scene Investigation and Latent Print Analysis. The opinions or assertions contained on this site are the private views of the author and are not to be construed as those of any professional organisation or policing body.
- Forensic Podcast -spot_img

A team of British and Canadian researchers has managed to successfully sequence the full genome of a living organism using a machine the size of a smartphone called the MinION. The miniaturisation breakthrough could allow for more personalised medical diagnosis and better research in the field.

The MinION was developed by Oxford Nanopore Technologies and is currently undergoing tests to evaluate the technology. Its tiny size and relatively low cost could allow scientists to perform much more advanced analysis away from a lab. “The amazing thing about this device is that it is many times smaller than a normal sequencer – you just attach it to a laptop using a USB cable,” explainedJared Simpson, a lead author on the study.

“It’s amazing,” added Luiz Shozo Ozaki from the Centre For The Study Of Biological Complexity, who plans to use the handheld device to study mosquitoes that transmit malaria and other diseases in the Amazon. “It’s something I can put in my pocket, take into the rainforest and get a genetic sequence right there.”

Accuracy

The drawbacks identified so far revolve around accuracy – the data it produces is currently less accurate than the data produced by a larger machine, meaning that strong bioinformatics tools are needed to correct errors. That was the focus of Simpson’s paper: “We were able to mathematically model nanopore sequencing and develop ways to reconstruct complete genomes off this tiny sequencer,” he said.

Once proven, it’s hoped that the device could be used to sequence tumour genomes, giving the option of more personalised diagnosis and treatment to cancer patients. “It’s not ready for prime time yet, but it is producing a lot of data,” said Gregory Buck, also from the Centre For The Study Of Biological Complexity. “We want to see it work, and we’re optimistic that it’s going to work.”

Source: TechRadar

- Advertisement -spot_img

More articles

- Advertisement -spot_img

Latest article